Previous 10 | Next 10 |
CAMBRIDGE, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and...
Only clinical-stage candidate for Huntington’s disease designed to selectively lower mutant HTT and spare wild-type HTT Adaptive trial design to enable faster optimization of dosing and decision-making on next steps for WVE-003; data to be generated through 2022 ...
CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced it will highlight its ADAR-mediated RNA editing c...
CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and...
CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced it will highlight its ADAR-mediated RNA editing (...
The following slide deck was published by Wave Life Sciences Ltd. in conjunction with their 2021 Q2 earnings call. For further details see: Wave Life Sciences Ltd. 2021 Q2 - Results - Earnings Call Presentation
Wave Life Sciences Ltd. (WVE) Q2 2021 Earnings Conference Call August 05, 2021 08:30 AM ET Company Participants Kate Rausch - Head, Investor Relations Paul Bolno - President & Chief Executive Officer Mike Panzara - Chief Medical Officer Head, Therapeutics Discovery & Development Palom...
Dosing underway in FOCUS-C9 clinical trial of WVE-004 in C9-ALS / C9-FTD – first oligonucleotide using PN backbone chemistry modifications in clinical study Recruitment ongoing for clinical trials in HD and DMD Generating clinical data in multiple trials through 2...
CAMBRIDGE, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and ...
Wave Life Sciences (WVE) announces that multiple participants have initiated dosing in the Phase 1b/2a FOCUS-C9 clinical trial evaluating WVE-004 as an investigational treatment for C9orf72-associated amyotrophic lateral sclerosis (C9-ALS) and frontotemporal dementia (C9-FTD). The FOCUS-C9 tr...
News, Short Squeeze, Breakout and More Instantly...
Wave Life Sciences Ltd. Company Name:
WVE Stock Symbol:
NASDAQ Market:
Wave Life Sciences Ltd. Website:
2024-07-17 15:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Statistically significant, potent, and durable allele-selective silencing: 46% mean reduction in CSF mutant huntingtin (mHTT) protein compared to placebo, preservation of wild-type huntingtin (wtHTT) protein, and generally safe and well-tolerated profile achieved in 30 mg multidose cohort ...
Presentation at the Obesity & Weight Loss Drug Development Summit to review Real World Evidence for the GLP-1 class and the opportunity for Wave’s INHBE program as a best-in-class approach for obesity designed to induce fat burning and preserve muscle mass with once or twice-annual sub...